TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma Meeting Abstract
| Authors: | Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Reguera, J. L.; Kuruvilla, J.; Jaeger, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; Kahl, B. S.; Ghesquieres, H.; Ardeshna, K.; Goto, H.; Barbui, A. M.; Abramson, J. S.; Borchmann, P.; Fleury, I.; Mielke, S.; Skarbnik, A.; de Vos, S.; Kamdar, M.; Karmali, R.; Viardot, A.; Farazi, T.; Fasan, O.; Lymp, J.; Vedal, M.; Nishii, R.; Avilion, A.; Papuga, J.; Nastoupil, L. J. |
| Abstract Title: | TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 602 |
| Language: | English |
| ACCESSION: | WOS:001159306702115 |
| DOI: | 10.1182/blood-2023-179474 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
